カタログ >
Randox Laboratories/ランドックス >
Cardiac Risk Multiplex Array

Cardiac Risk Multiplex Array
1 / 4ページ

カタログの抜粋

Cardiac Risk Prediction Array Comprehensive genetic risk assessment for CHD

Cardiac Risk Prediction Array Simultaneous genotyping of 19 SNPs for a reliable CHD risk assessment Introduction Coronary Heart Disease (CHD) is the leading cause of death in the developed world and its prevention is a core activity in general practice worldwide. For example, clinical guidelines from the Joint Cardiac Societies and NICE in the UK recommend that patients at greater than 20% risk of CHD in the next ten years should be classified as high risk and considered for intensive lifestyle intervention and lipid lowering therapy,1 primarily the prescription of statins. Current CHD risk...

カタログの2ページ目を開く

Response to statin treatment A fur ther impor tant SNP which can predict response to par ticular statin therapies has been included in the array. Individuals who are homozygous (frequency =0.13) for the risk allele are 17 times more likely to suffer from statin-induced myopathy when treated with high doses of simvastatin.8 Identifying patients with a higher risk of suffering statin-induced myopathy would allow clinicians to make more informed decisions when prescribing lipid lowering therapies. Cardiac Risk Prediction Array Protocol Step 1 Extraction Genomic DNA extracted from blood/saliva...

カタログの3ページ目を開く

Evidence Investigator Multiplexing...proven, perfected, evolved The Evidence Investigator is a semi-automated, benchtop biochip analyser which offers complete patient profiling. Save time and costs Multiplexing reduces time, labour and reagents associated with multiple individual tests Increase throughput For greater laboratory efficiency Consolidation Of immunoassays and molecular diagnostics, improving laboratory efficiency Result traceability Chain of custody features and bar coded reagents No hidden costs Package includes imaging module, PC and imaging software, thermoshaker, biochip...

カタログの4ページ目を開く